PerkinElmer: Q4 Earnings Insights

Shares of PerkinElmer PKI moved higher by 0.1% in after-market trading after the company reported Q4 results.

Quarterly Results

Earnings per share rose 193.33% over the past year to $3.96, which beat the estimate of $3.00.

Revenue of $1,355,000,000 higher by 68.22% year over year, which beat the estimate of $1,220,000,000.

Guidance

PerkinElmer Sees Q1 Adj. EPS $3.00+ vs $2.40 Est., Sales $1.19B+ vs $1.1B Est.; Sees FY21 Adj. EPS $8.50+ vs $8.88 Est., Sales $4.08B+ vs $4.17B Est.

Conference Call Details

Date: Feb 02, 2021

Time: 05:00 PM

ET Webcast URL: https://edge.media-server.com/mmc/p/hemakjuy

Technicals

52-week high: $162.70

Company's 52-week low was at $62.91

Price action over last quarter: Up 18.10%

Company Overview

PerkinElmer provides instruments, tests, services, and software solutions to the pharmaceutical, biomedical, chemical, environmental, and general industrial markets. The company operates in two segments: diagnostics, which includes prenatal screening and infectious-disease testing, and discovery and analytical solutions, composed of life science, industrial, environmental, and food applications. PerkinElmer offers products and services ranging from genetic screening to environmental analytical tools.